Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate

Abstract

Ductal adenocarcinoma of the prostate is a rare histological variant that only represents < 1% of prostate tumors. This histological variant has several important clinical implications with respect to their evolution, clinical prognosis, and treatment. We report the case of a 64-year-old patient with ductal adenocarcinoma of the prostate, which progresses to castration-resistant prostate cancer, that was treated with abiraterone acetate with good clinical response, to our knowledge, the first case of ductal adenocarcinoma of the prostate in treatment with abiraterone acetate.